<DOC>
	<DOCNO>NCT01287091</DOCNO>
	<brief_summary>This single-center , open-label , 3 part study . The study design determine relative bioavailability GDC-0980 capsule tablet formulation fast condition , effect high-fat ( feed ) meal pharmacokinetics GDC-0980 tablet , effect rabeprazole pharmacokinetics GDC-0980 tablet presence absence high-fat meal .</brief_summary>
	<brief_title>A 3-Part Study Determine Relative Bioavailability Capsule Tablet Formulations GDC-0980 , Effect Food , Effect Rabeprazole Pharmacokinetics Tablet</brief_title>
	<detailed_description />
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Inclusion Criteria Nonsmoking body mass index 18 32 kg/m2 Medically healthy determine absence clinically significant finding physical examination , medical history , vital sign measurement , clinical laboratory test , 12lead electrocardiogram ( ECGs ) Nonchildbearing potential , define either postmenopausal without recent history menorrhea surgically sterile Exclusion Criteria History clinical manifestation significant metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , endocrine , gastrointestinal , urological , neurological , psychiatric disorder , cancer History inflammatory arthritis History symptomatic hypotension History severe physical injury , direct impact trauma , neurological trauma within 6 month prior study start History seizure disorder History bipolar major depressive disorder History stomach intestinal surgery resection could potentially alter absorption and/or excretion orally administer drug exception appendectomy , hernia repair , cholecystectomy , allow History presence abnormal ECG History ventricular dysrhythmias risk factor ventricular dysrhythmias Abnormality chest xray Screening History alcoholism , drug abuse , drug addiction Used nicotinecontaining nicotinereplacement product within 6 month prior study start Participated investigational drug study receipt investigational study drug occur within 1 month 5 halflives prior study start Used prescription medications/products include monoamine oxidase inhibitor , thioridazine , pimozide , antidepressant within 1 month ( 2 week antibiotic ) prior study start , exception hormonereplacement therapy 2 week ' use narcotic pain Received vaccination immunization within 1 month prior study start Used PPIs histamine H2receptor antagonist within 1 month prior study start Hypersensitivity rabeprazole , component , derive product benzimidazoles ( Part 3 ) Poor peripheral venous access Received blood product within 2 month prior study start Positive urine drug alcohol screen Positive screen hepatitis B surface antigen , hepatitis C virus , human immunodeficiency virus type 1 2 Unable consume highfat meal ( Parts 2 3 ) Acute chronic condition would limit subject 's ability complete participate clinical study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>